Allergan To Pay $2.7M To End Certain Generic-Delay Claims
Allergan will pay a combined $2.7 million and allow judgment to be entered against it to resolve claims from three of the plaintiffs accusing the company's subsidiary of delaying generic competition...To view the full article, register now.
Already a subscriber? Click here to view full article